Lost in translation: barriers to implementing clinical immunotherapeutics for autoimmunity.
Induction of selective, autoantigen-specific tolerance is the "holy grail" for the treatment and prevention of autoimmune diseases. Despite successes in many differential murine models, rational and efficient translation to the clinic has been difficult. During the 5th Annual Federation of Clinical Immunological Societies (FOCIS) Meeting, May 12-16, 2005, in Boston, MA, a Kirin-sponsored "Ideashop" was convened to discuss this theme amongst scientists, clinicians, industry partners, and funding agencies.
von Herrath
Matthias G
MG
La Jolla Institute for Allergy and Immunology, San Diego, CA 92109, USA. Matthias@liai.org
Nepom
Gerald T
GT
D000818:Animals; D017849:Animals, Inbred Strains; D001327:Autoimmune Diseases / Q000191:economics / Q000276:immunology / Q000517:prevention & control / Q000628:therapy*; D035843:Biomedical Research / Q000191:economics / Q000639:trends*; D004195:Disease Models, Animal; D006801:Humans; D007167:Immunotherapy / Q000191:economics / Q000639:trends*; D014495:Universities